Efficacy and Safety of Cardiac Resynchronization Therapy in Chemotherapy-induced Cardiomyopathy: A Systematic Review

Overview

Journal Ann Noninvasive Electrocardiol

Specialty Cardiology & Vascular Diseases

Date 2023 Jul 12

PMID 37435629

Authors

Muhammad Shehram

Hiba Khalid

Hafiz Muhammad Shafique

Bakht Umer

Awais Zafar

Asif Ullah

Syed Muhammad Jawad Zaidi

Jawad Basit

Amin Mehmoodi

Jahanzeb Malik

Affiliations

Soon will be listed here.

Abstract

Objective: The aim of the study was to assess the efficacy of cardiac resynchronization therapy (CRT) in patients with chemotherapy-induced cardiomyopathy (CIC).

Methods: With the increasing incidence of CIC, the association of CRT with improvement in clinical outcomes, echocardiographic parameters, and New York Heart Classification (NYHA) class was assessed through this qualitative systematic review.

Results: The five studies included a total of 169 patients who underwent CRT after CIC, and of these, 61 (36.1%) patients were males. All studies showed an improvement in left ventricular ejection fraction (LVEF), among other echocardiographic parameters of LV volume. However, these findings are limited by short follow-up periods, small sample sizes, and the absence of a control group.

Conclusion: CRT was associated with improvement in all patient parameters with CIC.

Citing Articles

Efficacy and safety of cardiac resynchronization therapy in chemotherapy-induced cardiomyopathy: A systematic review.

Shehram M, Khalid H, Shafique H, Umer B, Zafar A, Ullah A Ann Noninvasive Electrocardiol. 2023; 28(5):e13070.

PMID: 37435629 PMC: 10475884. DOI: 10.1111/anec.13070.

References

Cardinale D, Colombo A, Bacchiani G, Tedeschi I, Meroni C, Veglia F . Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation. 2015; 131(22):1981-8. DOI: 10.1161/CIRCULATIONAHA.114.013777. View

Ezzeddine F, Saliba A, Jain V, Villarraga H, Herrmann J, Asirvatham S . Outcomes of cardiac resynchronization therapy in patients with chemotherapy-induced cardiomyopathy. Pacing Clin Electrophysiol. 2021; 44(4):625-632. PMC: 8772340. DOI: 10.1111/pace.14196. View

Patel D, Kumar A, Moennich L, Trulock K, Nemer D, Donnellan E . Cardiac resynchronisation therapy in anthracycline-induced cardiomyopathy. Heart. 2021; 108(4):274-278. DOI: 10.1136/heartjnl-2020-318333. View

Singh J, Solomon S, Fradley M, Barac A, Kremer K, Beck C . Association of Cardiac Resynchronization Therapy With Change in Left Ventricular Ejection Fraction in Patients With Chemotherapy-Induced Cardiomyopathy. JAMA. 2019; 322(18):1799-1805. PMC: 6865289. DOI: 10.1001/jama.2019.16658. View

Gulati G, Lagethon Heck S, Ree A, Hoffmann P, Schulz-Menger J, Fagerland M . Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 × 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol. Eur Heart J. 2016; 37(21):1671-80. PMC: 4887703. DOI: 10.1093/eurheartj/ehw022. View

Goorin A, Borow K, Goldman A, Williams R, Henderson I, Sallan S . Congestive heart failure due to adriamycin cardiotoxicity: its natural history in children. Cancer. 1981; 47(12):2810-6. DOI: 10.1002/1097-0142(19810615)47:12<2810::aid-cncr2820471210>3.0.co;2-4. View

Baech J, Hansen S, Lund P, Soegaard P, de Nully Brown P, Haaber J . Cumulative anthracycline exposure and risk of cardiotoxicity; a Danish nationwide cohort study of 2440 lymphoma patients treated with or without anthracyclines. Br J Haematol. 2018; 183(5):717-726. DOI: 10.1111/bjh.15603. View

Fadol A, Mouhayar E, Reyes-Gibby C . The Use of Cardiac Resynchronization Therapy in Cancer Patients with Heart Failure. J Clin Exp Res Cardiol. 2018; 3(1). PMC: 6022845. DOI: 10.15744/2394-6504.3.105. View

Moss A, Hall W, Cannom D, Klein H, Brown M, Daubert J . Cardiac-resynchronization therapy for the prevention of heart-failure events. N Engl J Med. 2009; 361(14):1329-38. DOI: 10.1056/NEJMoa0906431. View

10.

Shehram M, Khalid H, Shafique H, Umer B, Zafar A, Ullah A . Efficacy and safety of cardiac resynchronization therapy in chemotherapy-induced cardiomyopathy: A systematic review. Ann Noninvasive Electrocardiol. 2023; 28(5):e13070. PMC: 10475884. DOI: 10.1111/anec.13070. View

11.

Rickard J, Kumbhani D, Baranowski B, Martin D, Tang W, Wilkoff B . Usefulness of cardiac resynchronization therapy in patients with Adriamycin-induced cardiomyopathy. Am J Cardiol. 2010; 105(4):522-6. DOI: 10.1016/j.amjcard.2009.10.024. View

12.

Sami A, Mustafa B, Butt H, Ashraf Z, Ullah A, Babar F . Echocardiography- versus intracardiac electrocardiogram-based optimization of cardiac resynchronization therapy: A systematic review. Ann Noninvasive Electrocardiol. 2023; 28(2):e13040. PMC: 10023891. DOI: 10.1111/anec.13040. View